This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n5http://www.rxlist.com/cgi/generic3/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/wikipedia/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/pubchem-compound/
n32http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/drugbank/
n16http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n31http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/national-drug-code-directory/
n24http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00299/identifier/chemspider/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00299
rdf:type
n3:Drug
n3:description
Penciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. [Wikipedia]
n3:dosage
n30:271B4DF7-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 hours
n3:indication
Used to treat recurrent cold sores on the lips and face from various herpesvirus invections.
n3:manufacturer
n7:271B4DF4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00299 n32:DB00299
dcterms:title
Penciclovir
adms:identifier
n11:PA450839 n12:4725 n13:0067-6024-15 n14:PE2 n15:46506498 n17:7956 n18:Penciclovir n19:C07417 n20:D05407 n21:4563 n22:DB00299
n3:mechanismOfAction
Penciclovir has <i>in vitro</i> activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form. The monophosphate form of the drug is then converted to penciclovir triphosphate by cellular kinases. The intracellular triphosphate of penciclovir is retained <i>in vitro</i> inside HSV-infected cells for 10-20 hours, compared with 0.7-1 hour for acyclovir. <i>in vitro</i> studies show that penciclovir triphosphate selectively inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. Inhibition of DNA synthesis of virus-infected cells inhibits viral replication. In cells not infected with HSV, DNA synthesis is unaltered. Resistant mutants of HSV can occur from qualitative changes in viral thymidine kinase or DNA polymerase. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase are also resistant to penciclovir.
n3:packager
n7:271B4DF3-363D-11E5-9242-09173F13E4C5 n7:271B4DF2-363D-11E5-9242-09173F13E4C5
n3:patent
n16:2113080 n16:6579981 n16:5075445
n3:synonym
PCV PE2 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine Penciclovirum 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine
n3:toxicity
Symptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.
n8:hasAHFSCode
n28:84-04-06
n3:proteinBinding
Less than 20%.
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Penciclovir.htm
n24:hasConcept
n25:M0151646
foaf:page
n5:penciclovir.htm n23:penciclovir.html
n3:IUPAC-Name
n6:271B4DFC-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4E02-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4E01-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4DFE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4DFF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4E00-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4DFA-363D-11E5-9242-09173F13E4C5 n6:271B4E12-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4DF8-363D-11E5-9242-09173F13E4C5 n6:271B4DFB-363D-11E5-9242-09173F13E4C5 n6:271B4E14-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4DF9-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:D06BB06 n9:J05AB13
n3:H-Bond-Acceptor-Count
n6:271B4E08-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4E09-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4E03-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4E04-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4E06-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4E05-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4E07-363D-11E5-9242-09173F13E4C5
n3:absorption
Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n= 12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily.
n3:affectedOrganism
Herpes simplex virus
n3:casRegistryNumber
39809-25-1
n3:category
n3:containedIn
n31:271B4DF5-363D-11E5-9242-09173F13E4C5 n31:271B4DF6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4E0E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4E10-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4E11-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B4E13-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4E0D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4E0C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4E0F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4DFD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4E0A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4E0B-363D-11E5-9242-09173F13E4C5